drugset
drugset / Trial / NCT04927793

Absorption, Metabolism, and Excretion (AME) Study of [14C]EDP-938 in Healthy Male Subjects

NCT04927793 ↗

Phase 1 Completed 8 enrolled Enanta Pharmaceuticals, Inc
NaSingle-groupOpen-labelBasic science

Summary

A Phase 1, Open-label Study of the absorption, metabolism, and excretion of a single oral dose of \[14C\]EDP-938 in healthy male subjects.

Timeline

Start
2021-05-28
Primary completion
2021-07-04
Completion
2021-07-04

Drugs

EvaluationDrugModalityDoseRoute
Subject zelicapavir Small molecule — Oral

Indications

respiratory syncytial virus infectious disease